Molecular markers and targeted therapies for adrenocortical carcinoma

Clinical Endocrinology

Volumn 80, Issue 2, 2014, Pages 159-168

  Xu, Yunze ^a   Qi, Yicheng ^b   Zhu, Yu ^a,c   Ning, Guang ^b   Huang, Yiran ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIGITUMUMAB; GEFITINIB; GEMCITABINE; IMATINIB; LINSITINIB; MELANOCORTIN 2 RECEPTOR; MICRORNA; MOLECULAR MARKER; NVP AEW 541; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; STEROIDOGENIC FACTOR 1; THALIDOMIDE; VASCULOTROPIN;

ADRENAL CORTEX CARCINOMA; CHROMOSOME LOSS; CLINICAL TRIAL (TOPIC); COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84891872068     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12358     Document Type: Review

References (112)

1. Golden, S.H., Robinson, K.A., Saldanha, I., et al,. (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. Journal of Clinical Endocrinology and Metabolism, 94, 1853-1878.
2. Kebebew, E., Reiff, E., Duh, Q.Y., et al,. (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World Journal of Surgery, 30, 872-878. (Pubitemid 43724119)
3. Koschker, A.C., Fassnacht, M., Hahner, S., et al,. (2006) Adrenocortical carcinoma-improving patient care by establishing new structures. Experimental and Clinical Endocrinology & Diabetes, 114, 45-51.
4. Lehmann, T., &, Wrzesinski, T., (2012) The molecular basis of adrenocortical cancer. Cancer Genetics, 205, 131-137.
5. Sandrini, R., Ribeiro, R.C., &, DeLacerda, L., (1997) Childhood adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 82, 2027-2031.
6. Ribeiro, R.C., Sandrini, F., Figueiredo, B., et al,. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 98, 9330-9335. (Pubitemid 32743916)
7. Pinto, E.M., Billerbeck, A.E., Villares, M.C., et al,. (2004) Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arquivos Brasileiros De Endocrinologia E Metabologia 48, 647-650.
8. Lorea, C.F., Moreno, D.A., Borges, K.S., et al,. (2012) Expression profile of apoptosis-related genes in childhood adrenocortical tumors: low level of expression of BCL2 and TNF genes suggests a poor prognosis. European Journal of Endocrinology, 167, 199-208.
9. Bertherat, J., &, Bertagna, X., (2009) Pathogenesis of adrenocortical cancer. Best Practice and Research. Clinical Endocrinology and Metabolism, 23, 261-271.
10. Luton, J.P., Cerdas, S., Billaud, L., et al,. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine, 322, 1195-1201. (Pubitemid 20137851)
11. Zini, L., Porpiglia, F., &, Fassnacht, M., (2011) Contemporary management of adrenocortical carcinoma. European Urology, 60, 1055-1065.
12. Fassnacht, M., Libe, R., Kroiss, M., et al,. (2011) Adrenocortical carcinoma: a clinician's update. Nature Reviews Endocrinology, 7, 323-335.
13. Stojadinovic, A., Ghossein, R.A., Hoos, A., et al,. (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology, 20, 941-950. (Pubitemid 34141836)
14. Fassnacht, M., &, Allolio, B., (2009) Clinical management of adrenocortical carcinoma. Best Practice and Research. Clinical Endocrinology and Metabolism, 23, 273-289.
15. Icard, P., Goudet, P., Charpenay, C., et al,. (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery, 25, 891-897. (Pubitemid 32666390)
16. Allolio, B., &, Fassnacht, M., (2006) Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism, 91, 2027-2037. (Pubitemid 43854976)
17. Schteingart, D.E., Doherty, G.M., Gauger, P.G., et al,. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer, 12, 667-680. (Pubitemid 41483000)
18. Berruti, A., Fassnacht, M., Baudin, E., et al,. (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. Journal of Clinical Oncology, 28, e401-e402; author reply e403.
19. Abiven, G., Coste, J., Groussin, L., et al,. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism, 91, 2650-2655. (Pubitemid 44024632)
20. Soon, P.S., McDonald, K.L., Robinson, B.G., et al,. (2008) Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist, 13, 548-561. (Pubitemid 351872872)
21. Raymond, V.M., Everett, J.N., Furtado, L.V., et al,. (2013) Adrenocortical carcinoma is a lynch syndrome-associated cancer. Journal of Clinical Oncology, 31, 3012-3018.
22. de Fraipont, F., El Atifi, M., Cherradi, N., et al,. (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism, 90, 1819-1829. (Pubitemid 40464057)
23. de Reynies, A., Assie, G., Rickman, D.S., et al,. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology, 27, 1108-1115.
24. Soon, P.S., Libe, R., Benn, D.E., et al,. (2008) Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Annals of Surgery, 247, 157-164.
25. Sidhu, S., Marsh, D.J., Theodosopoulos, G., et al,. (2002) Comparative genomic hybridization analysis of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 87, 3467-3474. (Pubitemid 34816405)
26. Barlaskar, F.M., &, Hammer, G.D., (2007) The molecular genetics of adrenocortical carcinoma. Reviews in Endocrine & Metabolic Disorders, 8, 343-348.
27. Hollstein, M., Sidransky, D., Vogelstein, B., et al,. (1991) p53 mutations in human cancers. Science, 253, 49-53. (Pubitemid 21917115)
28. Brosh, R., &, Rotter, V., (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 9, 701-713.
29. Vogelstein, B., Lane, D., &, Levine, A.J., (2000) Surfing the p53 network. Nature, 408, 307-310.
30. Varley, J.M., McGown, G., Thorncroft, M., et al,. (1999) Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. American Journal of Human Genetics, 65, 995-1006. (Pubitemid 30462956)
31. Hisada, M., Garber, J.E., Fung, C.Y., et al,. (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute, 90, 606-611. (Pubitemid 28204804)
32. Malkin, D., Li, F.P., Strong, L.C., et al,. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238. (Pubitemid 120031831)
33. Reincke, M., Karl, M., Travis, W.H., et al,. (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism, 78, 790-794.
34. Libe, R., Groussin, L., Tissier, F., et al,. (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research, 13, 844-850. (Pubitemid 46340358)
35. Wagner, J., Portwine, C., Rabin, K., et al,. (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute, 86, 1707-1710. (Pubitemid 24354633)
36. Ragazzon, B., Libe, R., Gaujoux, S., et al,. (2010) Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Research, 70, 8276-8281.
37. DiGiammarino, E.L., Lee, A.S., Cadwell, C., et al,. (2002) A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Natural Structural Biology, 9, 12-16. (Pubitemid 34049172)
38. Latronico, A.C., Pinto, E.M., Domenice, S., et al,. (2001) An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 86, 4970-4973. (Pubitemid 33020551)
39. Achatz, M.I., Olivier, M., Le Calvez, F., et al,. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 245, 96-102. (Pubitemid 44959345)
40. Pinto, E.M., Billerbeck, A.E., Fragoso, M.C., et al,. (2005) Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. Journal of Clinical Endocrinology and Metabolism, 90, 2976-2981. (Pubitemid 40686352)
41. Gicquel, C., Bertagna, X., Gaston, V., et al,. (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research, 61, 6762-6767. (Pubitemid 32896498)
42. Maher, E.R., &, Reik, W., (2000) Beckwith-Wiedemann syndrome: imprinting in clusters revisited. Journal of Clinical Investigation, 105, 247-252. (Pubitemid 30094443)
43. Gicquel, C., Bertagna, X., Schneid, H., et al,. (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 78, 1444-1453. (Pubitemid 24181019)
44. Gicquel, C., Raffin-Sanson, M.L., Gaston, V., et al,. (1997) Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism, 82, 2559-2565. (Pubitemid 27337873)
45. Hoeflich, A., Reisinger, R., Lahm, H., et al,. (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Research, 61, 8601-8610. (Pubitemid 34013863)
46. Samani, A.A., Yakar, S., LeRoith, D., et al,. (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews, 28, 20-47. (Pubitemid 46220849)
47. Boulle, N., Logie, A., Gicquel, C., et al,. (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 83, 1713-1720. (Pubitemid 28501047)
48. Giordano, T.J., Thomas, D.G., Kuick, R., et al,. (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology, 162, 521-531. (Pubitemid 36267859)
49. Weber, M.M., Auernhammer, C.J., Kiess, W., et al,. (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology, 136, 296-303. (Pubitemid 27130054)
50. Doghman, M., El Wakil, A., Cardinaud, B., et al,. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Research, 70, 4666-4675.
51. Almeida, M.Q., Fragoso, M.C., Lotfi, C.F., et al,. (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 93, 3524-3531.
52. Barlaskar, F.M., Spalding, A.C., Heaton, J.H., et al,. (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism, 94, 204-212.
53. Maluf, D.F., de Oliveira, B.H., &, Lalli, E., (2011) Therapy of adrenocortical cancer: present and future. American Journal of Cancer Research, 1, 222-232.
54. Haluska, P., Worden, F., Olmos, D., et al,. (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology, 65, 765-773.
55. Carden, C.P., Frentzas, S., Langham, M., et al,. (2009) Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology, 27.
56. Kim, A.C., Reuter, A.L., Zubair, M., et al,. (2008) Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development, 135, 2593-2602.
57. Cadoret, A., Ovejero, C., Terris, B., et al,. (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene, 21, 8293-8301. (Pubitemid 35477869)
58. El Wakil, A., &, Lalli, E., (2011) The Wnt/beta-catenin pathway in adrenocortical development and cancer. Molecular and Cellular Endocrinology, 332, 32-37.
59. Gaujoux, S., Tissier, F., Groussin, L., et al,. (2008) Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 93, 4135-4140.
60. Tadjine, M., Lampron, A., Ouadi, L., et al,. (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clinical Endocrinology, 68, 264-270.
61. Tissier, F., Cavard, C., Groussin, L., et al,. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research, 65, 7622-7627. (Pubitemid 41297234)
62. Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S., et al,. (2010) Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Molecular Genetics, 19, 1561-1576.
63. Forbes, S.A., Bhamra, G., Bamford, S., et al,. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Current Protocols in Human Genetics Chapter 10, Unit 10 11.
64. Doghman, M., Cazareth, J., &, Lalli, E., (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism, 93, 3222-3225.
65. Schimmer, B.P., &, White, P.C., (2010) Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Molecular Endocrinology, 24, 1322-1337.
66. Lalli, E., (2010) Adrenocortical development and cancer: focus on SF-1. Journal of Molecular Endocrinology, 44, 301-307.
67. Pianovski, M.A., Cavalli, L.R., Figueiredo, B.C., et al,. (2006) SF-1 overexpression in childhood adrenocortical tumours. European Journal of Cancer, 42, 1040-1043.
68. Figueiredo, B.C., Cavalli, L.R., Pianovski, M.A., et al,. (2005) Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 90, 615-619. (Pubitemid 40279170)
69. Almeida, M.Q., Soares, I.C., Ribeiro, T.C., et al,. (2010) Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. Journal of Clinical Endocrinology and Metabolism, 95, 1458-1462.
70. Doghman, M., Karpova, T., Rodrigues, G.A., et al,. (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Molecular Endocrinology, 21, 2968-2987. (Pubitemid 350223508)
71. Lichtenauer, U.D., Duchniewicz, M., Kolanczyk, M., et al,. (2007) Pre-B-cell transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical growth and steroidogenesis. Endocrinology, 148, 693-704. (Pubitemid 46143171)
72. Sbiera, S., Schmull, S., Assie, G., et al,. (2010) High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinology and Metabolism, 95, E161-E171.
73. Doghman, M., Cazareth, J., Douguet, D., et al,. (2009) Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. Journal of Clinical Endocrinology and Metabolism, 94, 2178-2183.
74. Dallman, M.F., (1984) Control of adrenocortical growth in vivo. Endocrine Research, 10, 213-242. (Pubitemid 15018384)
75. Reincke, M., Mora, P., Beuschlein, F., et al,. (1997) Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 82, 3054-3058. (Pubitemid 27385671)
76. Chida, D., Nakagawa, S., Nagai, S., et al,. (2007) Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104, 18205-18210. (Pubitemid 350210845)
77. Beuschlein, F., Fassnacht, M., Klink, A., et al,. (2001) ACTH-receptor expression, regulation and role in adrenocortial tumor formation. European Journal of Endocrinology, 144, 199-206. (Pubitemid 32266286)
78. Parviainen, H., Schrade, A., Kiiveri, S., et al,. (2013) Expression of Wnt and TGF-beta pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathology, Research and Practice, 209, 503-509.
79. Kerbel, R.S., (2008) Tumor angiogenesis. New England Journal of Medicine, 358, 2039-2049. (Pubitemid 351656458)
80. Ferrara, N., &, Gerber, H.P., (2001) The role of vascular endothelial growth factor in angiogenesis. Acta Haematologica, 106, 148-156. (Pubitemid 34124153)
81. Zacharieva, S., Atanassova, I., Orbetzova, M., et al,. (2004) Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. European Journal of Endocrinology, 150, 345-349. (Pubitemid 38443785)
82. de Fraipont, F., El Atifi, M., Gicquel, C., et al,. (2000) Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism, 85, 4734-4741. (Pubitemid 32157660)
83. Kolomecki, K., Stepien, H., &, Narebski, J.M., (2000) Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours. Cytobios, 101, 55-64.
84. Kolomecki, K., Stepien, H., Bartos, M., et al,. (2001) Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine Regulations, 35, 9-16. (Pubitemid 33711948)
85. Xu, Y.Z., Zhu, Y., Shen, Z.J., et al,. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine, 40, 445-451.
86. Bernini, G.P., Moretti, A., Bonadio, A.G., et al,. (2002) Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism, 87, 4961-4965. (Pubitemid 35316333)
87. Wortmann, S., Quinkler, M., Ritter, C., et al,. (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 162, 349-356.
88. Kamio, T., Shigematsu, K., Sou, H., et al,. (1990) Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Human Pathology, 21, 277-282. (Pubitemid 20081227)
89. Nakamura, M., Miki, Y., Akahira, J., et al,. (2009) An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocrine Pathology, 20, 17-23.
90. Adam, P., Hahner, S., Hartmann, M., et al,. (2010) Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 23, 1596-1604.
91. Quinkler, M., Hahner, S., Wortmann, S., et al,. (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism, 93, 2057-2062. (Pubitemid 351831515)
92. Berruti, A., Ferrero, A., Sperone, P., et al,. (2008) Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 13, 497-509.
93. Huang, F., Greer, A., Hurlburt, W., et al,. (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Research, 69, 161-170.
94. West, A.N., Neale, G.A., Pounds, S., et al,. (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Research, 67, 600-608. (Pubitemid 46192198)
95. van Nederveen, F.H., &, de Krijger, R.R., (2007) Precursor lesions of the adrenal gland. Pathobiology, 74, 285-290. (Pubitemid 47450574)
96. Chacon, R., Tossen, G., Loria, F.S., et al,. (2005) CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. Journal of Clinical Oncology, 23, 1579-1580.
97. Zsippai, A., Szabo, D.R., Szabo, P.M., et al,. (2011) mRNA and microRNA expression patterns in adrenocortical cancer. American Journal of Cancer Research, 1, 618-628.
98. Patterson, E.E., Holloway, A.K., Weng, J., et al,. (2011) MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer, 117, 1630-1639.
99. Schmitz, K.J., Helwig, J., Bertram, S., et al,. (2011) Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of Clinical Pathology, 64, 529-535.
100. Tombol, Z., Szabo, P.M., Molnar, V., et al,. (2009) Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer, 16, 895-906.
101. Ladeiro, Y., Couchy, G., Balabaud, C., et al,. (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47, 1955-1963. (Pubitemid 351952843)
102. Soon, P.S., Tacon, L.J., Gill, A.J., et al,. (2009) miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clinical Cancer Research, 15, 7684-7692.
103. Soon, P.S., Gill, A.J., Benn, D.E., et al,. (2009) Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer, 16, 573-583.
104. Chabre, O., Libe, R., Assie, G., et al,. (2013) Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocrine-Related Cancer, 20, 579-594.
105. Etheridge, A., Lee, I., Hood, L., et al,. (2011) Extracellular microRNA: a new source of biomarkers. Mutation Research, 717, 85-90.
106. Singh, P., Soon, P.S., Feige, J.J., et al,. (2012) Dysregulation of microRNAs in adrenocortical tumors. Molecular and Cellular Endocrinology, 351, 118-128.
107. Esteller, M., (2008) Epigenetics in cancer. New England Journal of Medicine, 358, 1148-1159.
108. Rechache, N.S., Wang, Y., Stevenson, H.S., et al,. (2012) DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 97, E1004-E1013.
109. Fonseca, A.L., Kugelberg, J., Starker, L.F., et al,. (2012) Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer, 51, 949-960.
110. Wortmann, S., Quinkler, M., Ritter, C., et al,. (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 162, 349-356.
111. Gross, D.J., Munter, G., Bitan, M., et al,. (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer, 13, 535-540. (Pubitemid 43886675)
112. Samnotra, V., Vassilopoulou-Sellin, R., &, Fojo, A.T., (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal of Clinical Oncology.